Media OutReach
DHL Supply Chain strengthens Life Sciences & Healthcare infrastructure with new Pharma Hub in Singapore
- The new facility is part of DHL Group’s €500 million investment in Asia Pacific for the sector
- Regional capabilities are expanded to support global healthcare trends and address growing sector demands
SINGAPORE – Media OutReach Newswire – 14 April 2025 – DHL Supply Chain, the global leader in contract logistics, launched a new Pharma Hub in Singapore, a dedicated facility for pharmaceutical logistics. The €10 million facility is part of DHL Group’s €500 million investment into Asia Pacific to bolster its Life Sciences and Healthcare (LSHC) infrastructure across all business units.
This strategic initiative reflects DHL Group’s global focus on the healthcare sector as part of its Strategy 2030, which introduced the new “DHL Health Logistics” sector brand to drive cross-divisional growth. The LSHC sector currently contributes EUR5 billion to DHL’s global revenue, underscoring its significance in the Group’s growth strategy.

“At DHL Supply Chain, we are committed to supporting the rapidly growing LSHC sector in Asia Pacific where there is a growing demand for transformative healthcare solutions due to longer lifespans, personalized treatments and rising consumer expectations. By 2030, the region’s medical market is projected to reach USD138 billion (~€127 billion), reflecting the critical need for resilient and efficient supply chains. As part of DHL Group’s Strategy 2030, we have invested ahead to strengthen our infrastructure and capabilities, ensuring we can meet the evolving and increasingly complex needs of our customers.
Our investment goes beyond building warehouses or expanding networks. It is about building a foundation across all our business units that enables faster, more reliable delivery of life-saving medicines and healthcare products. In a region where healthcare demand is surging, we enable our customers to focus on innovation and patient care. At the same time, we handle the complexities of supply chain management across all logistics touchpoints – from storage, order fulfillment, and distribution to global shipping and last-mile delivery. This is how we deliver real value: by turning challenges into opportunities and ensuring that every link in the healthcare supply chain works seamlessly,” explained Javier Bilbao, CEO, DHL Supply Chain Asia Pacific.
The new 8,200 square meters Pharma Hub at 8 Jurong Pier in Singapore features specialized temperature-controlled zones including ambient (15°C to 25°C) and cold room (2°C to 8°C), ensuring precise storage conditions for sensitive healthcare products. It is Good Manufacturing Practice (GMP) compliant with advanced cold chain infrastructure, including airtight loading docks and dedicated anterooms, ensures uninterrupted temperature stability throughout the logistics process. Future plans are in place to enable pharma related value-added services including redressing activities. Strategically located near Tuas Bio-Medical Park, the Pharma Hub offers seamless connectivity to Changi Airport and Tuas Mega Port, enabling efficient regional and global distribution for pharmaceutical partners.
“Singapore is laser-focused on becoming a global leader in life sciences and medtech innovation. The country’s ambitions are backed by investments, such as a top-up of SGD$3 billion (~€2 billion) in Budget 2025 to attract investments in sectors like semiconductors and life sciences, as well as other key initiatives, including the National Research, Innovation and Enterprise (RIE).
With the new Pharma Hub in Jurong, we have over 36,000 square meters of warehouse space in Singapore dedicated to LSHC operations. Our current operations include being the regional distribution centers for multiple medical device multi-nationals, clinical trials support and other value-added services,” said Eunis Hew, Managing Director, DHL Supply Chain Singapore.
A successful LSHC supply chain requires several critical factors – robust warehouse infrastructure, skilled personnel and innovative solutions. Together, these elements enable DHL Supply Chain to meet the unique demands of the healthcare industry and deliver exceptional value to customers.
Supporting growth with robust infrastructure
Even before the recent announcement of DHL Group’s €2 billion investment into the sector, DHL Supply Chain has already made strategic early investments in the region. These key projects, supporting the growing LSHC industry and helping customers navigate evolving demands, include:
- €28 million in upgrades to automation, robotics, and expanded floor space at LSHC sites in New South Wales, Australia.
- A €26 million automated LSHC site in Auckland, New Zealand, featuring advanced technologies like automated pallet storage, tote robotic storage, and Goods-to-Person (GTP) systems.
- Upcoming LSHC sites in South Korea to support critical deliveries to hospitals for medical devices and clinical logistics.
- An upcoming LSHC site in Bhiwandi, India, further expanding DHL’s footprint in the region.
DHL Supply Chain’s extensive network of Good Distribution Practice (GDP)/ GMP-compliant facilities, featuring specialized temperature zones, humidity control, and uninterrupted cold chain capabilities, ensures the integrity of sensitive products such as pharmaceuticals and medical devices. Its specialized logistics solutions, including multi-temperature storage, transport, and complex and customized white glove express delivery for extremely time- and temperature-sensitive deliveries, position it to address structural shifts in the LSHC market.
Globally, DHL Group has announced an investment of €2 billion by 2030 to boost integrated healthcare solutions. It also recently acquired CRYOPDP, a specialty courier providing end-to-end temperature-controlled solutions and white-glove services designed for the LSHC industry.
Skilled personnel with the right expertise to navigate complexities
Many pharmaceutical products require strict temperature control during storage and transportation, as well as adherence to stringent LSHC industry regulations. Skilled personnel are crucial in managing cold chain logistics, ensuring products remain within specified temperature ranges to maintain efficacy and safety. These professionals also navigate complex regulations and ensure compliance with local and international laws governing the storage, handling, and transportation of medical products.
With over 2,600 healthcare logistics experts and more than 40 full-time pharmacists in Asia Pacific, DHL Supply Chain manages the complexities of healthcare logistics for its customers. From regulatory compliance to proper product handling, DHL Supply Chain’s trained team ensures that every step of the supply chain operates seamlessly and efficiently.
Innovative solutions to drive efficiency and resilience
Innovation is at the heart of DHL Supply Chain’s LSHC operations. DHL drives efficiency and enables proactive decision-making by integrating automation, robotics, and AI-powered tracking systems into its operations. For example:
- Automated pallet storage and retrieval systems, along with GTP technology, streamline warehouse operations.
- Predictive analytics mitigate risks and improve decision-making.
- Control Tower technology provides real-time visibility and coordination across the supply chain.
- The Service Logistics network supports medical equipment manufacturers with aftermarket inventory storage, time-critical parts delivery, and compliance management.
By continuously investing in innovative solutions, DHL Supply Chain ensures its operations are equipped to meet the evolving needs of the healthcare sector, from research and development to patient delivery.
“Modern healthcare depends on more than just a physician’s expertise. It requires scale, connectivity, and constant collaboration between manufacturers, researchers and medical experts worldwide. Healthcare can only work if its logistics do too,” Bilbao added.
With the investments in new additions and expanded capabilities, DHL Supply Chain will operate over 80 facilities with over 700,000 square meters of fully compliant warehousing space in 13 countries across Asia Pacific.
Hashtag: #DHL
The issuer is solely responsible for the content of this announcement.
DHL – The logistics company for the world
Media OutReach
Asia Coach Group Partners with Veteran Business Consultant Rick Tam to Launch “Business Breakthrough” Programme for Hong Kong SMEs
Challenging Business Environment Demands New Solutions
Hong Kong’s SMEs are facing unprecedented operational pressures. According to a survey by CPA Australia, 37% of small businesses in Hong Kong struggle to obtain external financing. Data from Airwallex further reveals that 96% of SMEs have experienced cash flow difficulties in the past year. With property asset values declining, banks’ insistence on property collateral for loans has left many enterprises in financial distress.
Responding to Market Needs with Systematic Business Upgrade Solutions
“Hong Kong has never lacked capital—what’s missing is the mechanism to connect businesses with it,” Rick Tam noted. The programme addresses common pain points faced by local SMEs, including declining profits, low business valuations, tight cash flow, and recruitment challenges. Built upon the four-pillar framework of “Commerce, Strategy, Breakthrough, and Structure,” the curriculum covers stabilising cash flow and enhancing financial flexibility, repositioning businesses and improving client quality, reshaping product value and expanding profit margins, as well as systematising operations and attracting investors. The programme commits to helping participants improve cash flow, increase business value, and strengthen their business models within 90 days.
Four Practical Tools for Immediate Application
Participants will acquire four core tools: the “Cash Flow Vortex System” for rapid assessment of financial status and establishing safety buffers; the “A.T.C. Client Leverage Ladder” for repositioning and enhancing client value; the “High-Value Breakthrough Method” for creating products with greater value and trust; and the “Marketing Triangle Matrix” for integrating human resources, client bases, and operational systems to plan business expansion. The programme adopts a six-step progressive model—from restructuring business models, improving profit margins, attracting capital injection, building high-performance teams, and systematising operations, to ultimately helping business owners reclaim their time and freedom.
Instructor Credentials
Programme instructor Rick Tam is a graduate of the University of Hong Kong’s Business School and currently serves as CEO of two family offices and chief consultant to several others. He holds the CFPCM Certified Financial Planner designation. Tam has founded more than nine brands spanning wealth management, securities, and food and beverage sectors, and has guided over 1,000 participants through business expansion.
As Hong Kong’s economy seeks transformation, channelling capital precisely into the real economy through the “Business Breakthrough” approach offers more than a lifeline for SMEs—it injects vital momentum into Hong Kong’s long-term economic development.
Hashtag: #RickTam #AsiaCoach
The issuer is solely responsible for the content of this announcement.
Media OutReach
Zuellig Pharma Strengthens Consumer Healthcare Portfolio with the Acquisition of Zam-Buk® and Vapex® Brands from Bayer
Zam-Buk® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex® is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex® has built meaningful brand recognition, particularly in Thailand.
The acquisition of the brands supports Zuellig Pharma’s strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company’s second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.
Hashtag: #ZuelligPharma #ConsumerHealthcare #ConsumerHealth #Healthcare #Pharmaceuticals #Zambuk #Vapex #Bayer
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Media OutReach
International Entertainment Corporation to Hold EGM on 26 February 2026 for Proposed Convertible Notes Issuance
DigiPlus Interactive Corp., named as one of the Fortune Southeast Asia 500, together with its subsidiaries, is an innovative digital entertainment group in the Philippines and is a leader in the casinos and gaming industry. On 17 November 2025, the Company entered into the Subscription Agreement with the Subscriber, pursuant to which the Company conditionally agreed to issue and the Subscriber conditionally agreed to subscribe for the Notes in two tranches with a maturity of five years and an interest rate of 3% per annum.
Upon full conversion of the Notes at the initial Conversion Price, a total of 1,600,000,000 Shares will be issued by the Company, representing approximately 53.89% of the issued share capital of the Company as enlarged by the issue and allotment of the Conversion Shares. As such, the Subscriber will be obliged to make a mandatory general offer pursuant to Rule 26.1 of the Takeovers Code, unless the Whitewash Waiver is granted and approved.
The initial Conversion Price of HK$1.00 per Conversion Share represents a discount of approximately 3.85% to the closing price of HK$1.04 per Share as quoted on the Stock Exchange on the Latest Practicable Date (6 February 2026).
The board of Directors (the “Board“) believes that the Subscription would be beneficial to improving and strengthening the Group’s liquidity and financial position on a longer-term basis. In the event that the Subscriber converts part or the full amount of the Notes into the Conversion Shares, it will also broaden the shareholder and capital base of the Company. The Group intends to apply part of the net proceeds raised from the issuance of the Notes of approximately HK$489.22 million for the early repayment of the Promissory Notes and interest accrued thereon (the “PN Repayment“), and approximately HK$392.39 million to early repay the Secured Bank Borrowing to achieve immediate interest savings.
The remaining net proceeds will primarily be used for funding the Investment Commitment and attractive investment/business opportunity(ies); and as general working capital of the Group. The Investment Commitment is currently expected to include capital investments for acquisition of land for the expansion of the Group’s integrated resort in Manila City in the Philippines (the ”Hotel”) and the construction of additional hotel rooms, for provision of other amenities of the integrated resort, and for ongoing upgrades, refurbishments and renovations to the facilities and infrastructures of both the Hotel and the Group’s existing casino (the “Casino“).
The Independent Board Committee, which comprises all the independent non-executive Directors, is of the opinion that (i) the terms of the Subscription Agreement are on normal commercial terms, and the terms of the Subscription, the Whitewash Waiver and the Special Deal (the PN Repayment to the PN Holder) are fair and reasonable so far as the Independent Shareholders are concerned; and (ii) the Subscription, the Whitewash Waiver and the Special Deal are in the interests of the Company and the Shareholders as a whole and as far as the Independent Shareholders are concerned. It, therefore, recommends the Independent Shareholders to vote in favour of the relevant resolution(s) to be proposed at the EGM.
Hashtag: #InternationalEntertainmentCorporation
The issuer is solely responsible for the content of this announcement.
About International Entertainment Corporation (HKEX: 1009)
International Entertainment Corporation is an investment holding company. The Company and its subsidiaries are principally involved in hotel operations, operating the gaming business under provisional licence and leasing of gaming venues at the hotel complex of the Group in Metro Manila in the Republic of the Philippines to a tenant for authorized gaming operation and live poker events in Macau.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn










